期刊
DIABETES & METABOLISM JOURNAL
卷 45, 期 6, 页码 954-959出版社
KOREAN DIABETES ASSOC
DOI: 10.4093/dmj.2020.0173
关键词
Diabetes mellitus; type 2; Drug therapy; combination; Glycated hemoglobin A; Korea; Metformin; Vildagliptin
In the VERIFY study conducted in Korea between 2012 and 2014, early combination (EC) treatment significantly reduced the risk of initial treatment failure compared to MET monotherapy in newly diagnosed type 2 diabetes mellitus patients, with consistently lower HbA1c levels achieved by patients receiving EC treatment.
We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY study from Korea (n=39). Primary endpoint was time to initial treatment failure (TF) (glycosylated hemoglobin [HbA1c]>= 7.0% at two consecutive scheduled visits after randomization [end of period 1]). Time to second TF was assessed when both groups were receiving and failing on the combination (end of period 2). With EC the risk of initial TF significantly reduced by 78% compared to MET (n=3 [15%] vs. n=10 [58.7%], P=0.0228). No secondary TF occurred in EC group versus five patients (29.4%) in MET. Patients receiving EC treatment achieved consistently lower HbA1c levels. Both treatment approaches were well tolerated with no hypoglycaemic events. In Korean patients with newly diagnosed T2DM, EC treatment significantly and consistently improved the long-term glycaemic durability as compared with MET.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据